Markets

The Medicines Co. Settles Angiomax Patent Dispute with Sun - Analyst Blog

The Medicines CompanyMDCO announced that it has entered into a settlement agreement with Sun Pharmaceutical Industries Ltd. in connection with the patent litigation regarding its lead drug, Angiomax.

Sun Pharma had challenged a couple of the Medicine Company's patents (U.S. Patent No. 7,582,727 and U.S. Patent No. 7,598,343) covering Angiomax. The patents, which are listed in the Orange Book, are slated to expire on Jul 27, 2028.

The patent infringement dispute dates back to Oct 2011, when The Medicines Company had received a Paragraph IV Certification Notice Letter from Sun Pharma notifying the former company that it has submitted an abbreviated new drug application to the FDA for the approval of a generic version of Angiomax. The Medicines Company had subsequently filed a patent infringement lawsuit against Sun Pharma.

Under the terms of the settlement agreement, Sun Pharma can bring to market a generic version of Angiomax in the U.S. on or before Jun 30, 2019, under certain limited circumstances.

Meanwhile, The Medicines Company remains entangled in patent infringement litigation for Angiomax with several companies including Hospira Inc. HSP . Last year, Hospira had received a favorable court ruling in the Angiomax patent infringement lawsuit. Although The Medicines Company has appealed the ruling, a decision in favor of Hospira could result in the entry of generic Angiomax as early as Jun 15, 2015.

Angiomax is The Medicines Company's lead product, with U.S. sales accounting for almost 83% of total revenues in 2014. Needless to say, the earlier-than-expected entry of generics will be a major setback for the company. We note that The Medicines Company did not provide any guidance for 2015; the company may provide guidance once a decision in the Hospira case is announced.

The Medicines Company carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the health care sector include Lannett Company, Inc. LCI and Cambrex Corp. CBM . Both the companies sport a Zacks Rank #1 (Strong Buy).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

MEDICINES CO (MDCO): Free Stock Analysis Report

HOSPIRA INC (HSP): Free Stock Analysis Report

CAMBREX CORP (CBM): Free Stock Analysis Report

LANNETT INC (LCI): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

LCI

Other Topics

Stocks

Latest Markets Videos

    Zacks

    Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at www.zacks.com.

    Learn More